A detailed history of Northern Trust Corp transactions in Cassava Sciences Inc stock. As of the latest transaction made, Northern Trust Corp holds 395,780 shares of SAVA stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
395,780
Previous 378,343 4.61%
Holding current value
$10.5 Million
Previous $4.67 Million 149.29%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$9.57 - $35.08 $166,872 - $611,689
17,437 Added 4.61%
395,780 $11.6 Million
Q2 2024

Aug 14, 2024

SELL
$12.35 - $26.11 $5,866 - $12,402
-475 Reduced 0.13%
378,343 $4.67 Million
Q1 2024

May 14, 2024

SELL
$18.44 - $26.41 $163,157 - $233,675
-8,848 Reduced 2.28%
378,818 $7.69 Million
Q4 2023

Feb 13, 2024

BUY
$12.64 - $30.11 $177,364 - $422,503
14,032 Added 3.76%
387,666 $8.73 Million
Q3 2023

Nov 13, 2023

BUY
$16.64 - $25.32 $49,853 - $75,858
2,996 Added 0.81%
373,634 $6.22 Million
Q2 2023

Aug 11, 2023

BUY
$21.59 - $27.88 $220,541 - $284,794
10,215 Added 2.83%
370,638 $9.09 Million
Q1 2023

May 15, 2023

BUY
$23.46 - $36.44 $184,864 - $287,147
7,880 Added 2.24%
360,423 $8.69 Million
Q4 2022

Feb 13, 2023

SELL
$27.82 - $44.16 $10,961 - $17,399
-394 Reduced 0.11%
352,543 $10.4 Million
Q3 2022

Nov 14, 2022

SELL
$16.33 - $51.06 $88,328 - $276,183
-5,409 Reduced 1.51%
352,937 $14.8 Million
Q2 2022

Aug 12, 2022

SELL
$17.22 - $38.47 $105,834 - $236,436
-6,146 Reduced 1.69%
358,346 $10.1 Million
Q1 2022

May 13, 2022

SELL
$32.6 - $53.05 $499,921 - $813,521
-15,335 Reduced 4.04%
364,492 $13.5 Million
Q4 2021

Feb 08, 2022

SELL
$36.77 - $90.91 $30,445 - $75,273
-828 Reduced 0.22%
379,827 $16.6 Million
Q3 2021

Nov 15, 2021

BUY
$41.79 - $135.3 $6.11 Million - $19.8 Million
146,291 Added 62.42%
380,655 $23.6 Million
Q2 2021

Aug 13, 2021

SELL
$32.15 - $89.72 $3.41 Million - $9.51 Million
-105,957 Reduced 31.13%
234,364 $20 Million
Q1 2021

May 12, 2021

SELL
$7.09 - $87.95 $61,661 - $764,901
-8,697 Reduced 2.49%
340,321 $15.3 Million
Q4 2020

Feb 11, 2021

BUY
$6.79 - $12.25 $617,333 - $1.11 Million
90,918 Added 35.23%
349,018 $2.38 Million
Q3 2020

Nov 16, 2020

SELL
$2.86 - $11.51 $19,079 - $76,783
-6,671 Reduced 2.52%
258,100 $2.97 Million
Q2 2020

Aug 14, 2020

BUY
$2.04 - $9.64 $466,370 - $2.2 Million
228,613 Added 632.26%
264,771 $815,000
Q1 2020

May 14, 2020

BUY
$3.26 - $9.65 $42,653 - $126,260
13,084 Added 56.7%
36,158 $148,000
Q4 2019

Feb 14, 2020

BUY
$1.1 - $6.12 $5,929 - $32,986
5,390 Added 30.48%
23,074 $120,000
Q3 2019

Nov 13, 2019

SELL
$1.04 - $1.45 $1,040 - $1,450
-1,000 Reduced 5.35%
17,684 $21,000
Q1 2019

May 13, 2019

BUY
$0.92 - $1.29 $17,189 - $24,102
18,684 New
18,684 $24,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.06B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.